AbbVie PE Ratio 2010-2018 | ABBV

Current and historical p/e ratio for AbbVie (ABBV) from 2010 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of November 13, 2018 is 11.98.
AbbVie PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-13 88.22 18.23
2018-09-30 94.58 $4.84 19.54
2018-06-30 91.73 $4.04 22.71
2018-03-31 92.74 $3.97 23.36
2017-12-31 94.09 $3.29 28.60
2017-09-30 85.85 $4.11 20.89
2017-06-30 69.44 $4.07 17.06
2017-03-31 61.78 $3.86 16.01
2016-12-31 58.76 $3.63 16.19
2016-09-30 58.63 $3.70 15.85
2016-06-30 57.05 $3.47 16.44
2016-03-31 52.14 $3.32 15.70
2015-12-31 53.48 $3.12 17.14
2015-09-30 48.65 $1.69 28.79
2015-06-30 59.65 $1.26 47.34
2015-03-31 51.54 $1.11 46.43
2014-12-31 57.17 $1.09 52.45
2014-09-30 50.08 $2.30 21.77
2014-06-30 48.56 $2.59 18.75
2014-03-31 43.83 $2.57 17.05
2013-12-31 44.67 $2.56 17.45
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.913B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.684B 18.32
Pfizer (PFE) United States $262.581B 14.80
Novartis AG (NVS) Switzerland $204.469B 17.47
Merck (MRK) United States $201.378B 17.45
Eli Lilly (LLY) United States $119.915B 21.08
Sanofi (SNY) France $111.886B 13.85
Novo Nordisk (NVO) Denmark $108.835B 17.67
AstraZeneca (AZN) United Kingdom $103.621B 12.86
GlaxoSmithKline (GSK) United Kingdom $101.752B 13.68
Bristol-Myers Squibb (BMY) United States $86.262B 14.21